BVS - Company ID 0001665988
The table below shows Bioventus Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $8.93M | -$19.33M | -$6.00M | $2.49M | -$21.02M | -$18.04M |
| Capital expenditure | $574.00K | $826.00K | $291.00K | $3.56M | $2.96M | $1.37M |
| Investing cash flow | -$574.00K | -$826.00K | -$1.00M | -$15.07M | -$4.67M | -$46.65M |
| Dividends paid | - | - | - |
Bioventus Inc. reported operating cash flow of $74.67M for fiscal year 2025. That is up 92.5% from $38.80M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from $40.71M (FY 2019) to $74.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$23.14M | $947.00K | -$4.24M | $27.38M | $9.21M | $107.53M |